Pharmaceutical marketer price disclosure: Vermont
Vermont law 33 V.S.A. § 2005a requires pharmaceutical marketers to disclose to Vermont doctors and other prescribers the prices of the drugs they market as well as the prices of others drugs in the same therapeutic class.
This page allows those doctors and other prescribers access to this information for applicable products that are manufactured and marketed by AstraZeneca.
Please choose a product from the list, and select either "Long form" or "Short form" below.
| Medicine name | ||
|---|---|---|
| BRILINTA™ (ticagrelor) Tablets | Long form (PDF) | Short form (PDF) |
| CALQUENCE® (acalabrutinib) capsules | Long form (PDF) | Short form (PDF) |
| CRESTOR® (rosuvastatin calcium) Tablets | Long form (PDF) | Short form (PDF) |
| DALIRESP® (roflumilast) Tablets | Long form (PDF) | Short form (PDF) |
| FARXIGA™ (dapagliflozin) Tablets | Long form (PDF) | Short form (PDF) |
| IRESSA® (gefitinib) Tablets | Long form (PDF) | Short form (PDF) |
| KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release) Tablets | Long form (PDF) | Short form (PDF) |
| LYNPARZA™ (olaparib) Capsules | Long form (PDF) | Short form (PDF) |
| NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules | Long form (PDF) | Short form (PDF) |
| ONGLYZA™ (saxagliptin) Tablets | Long form (PDF) | Short form (PDF) |
| QTERN® (dapagliflozin and saxagliptin) | Long form (PDF) | Short form (PDF) |
| SEROQUEL® (quetiapine) Tablets | Long form (PDF) | Short form (PDF) |
| TAGRISSO™ (osimertinib) Tablets | Long form (PDF) | Short form (PDF) |
| XIGDUO™ XR (dapagliflozin and metformin hydrochloride) Tablets | Long form (PDF) | Short form (PDF) |